Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Patient Preference × Sunitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 113 Kidney Neoplasms 36 Neoplasms 31 Neoplasm Metastasis 27 Breast Neoplasms 27 Gastrointestinal Stromal Tumors 26 Carcinoma, Non-Small-Cell Lung 20 Prostatic Neoplasms 12 Urinary Bladder Neoplasms 11 Glioblastoma 11 Colorectal Neoplasms 11 Pancreatic Neoplasms 9 Lung Neoplasms 9 Carcinoma 9 Brain Neoplasms 9 Melanoma 8 Stomach Neoplasms 7 Sarcoma 7 Neuroendocrine Tumors 7 Carcinoma, Hepatocellular 7 Adenoma, Islet Cell 7 Thyroid Neoplasms 6 Small Cell Lung Carcinoma 6 Ovarian Neoplasms 6 Clear-cell metastatic renal cell carcinoma 6 Uveal Melanoma 5 Solid Tumors 5 Multiple Myeloma 5 Liver Neoplasms 5 Leukemia, Myeloid, Acute 5

Interventions

pertuzumab 1 pazopanib 1 enzalutamide 1 delta 24-sterol reductase 1 decitabine and cedazuridine drug combination 1 daratumumab 1 apalutamide 1 Validation Studies as Topic 1 Trastuzumab 1 Tape Recording 1 Surgical Procedures, Operative 1 Sunitinib 1 Radiotherapy 1 Pilot Projects 1 Opdualag 1 Nivolumab 1 Injections, Subcutaneous 1 Focus Groups 1 Bandages, Hydrocolloid 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01064310 2017-04-17

PISCES

Novartis

Phase 3 Completed

169 enrolled 16 charts

Carcinoma, Renal Cell, Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon ⚡